Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study

Abstract

Introduction This study aims to compare the safety and efficacy of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction (AMI) who were undergoing primary percutaneous coronary intervention (PPCI). Material and methods The study is a prospective, natural, and selective interventional trial based on real-world data for 482 AMI patients. Results At the end of the follow-up, the two groups demonstrated similar major adverse cardiovascular and cerebrovascular events (MACCE) and bleeding rates. After propensity score matching (PSM), the fondaparinux group showed greater advantages in reducing MACCE and bleeding events. Conclusions The anticoagulation strategy of bivalirudin bridging fonda­parinux seems to be superior to that of bivalirudin bridging enoxaparin in patients with AMI undergoing PPCI.

Keywords

• fondaparinux
• bivalirudin
• enoxaparin
• acute myocardial infarction
• primary percutaneous coronary intervention